Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
Status:
Terminated
Trial end date:
2015-09-30
Target enrollment:
Participant gender:
Summary
In this multi-center international study, our aim is to determine the effectiveness of HCQ
for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients
without systemic autoimmune diseases.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital for Special Surgery, New York
Collaborators:
AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking APS ACTION NY Community Trust Fund The New York Community Trust